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The herpes simplex virus type 1 (HSV-1) UL12 gene encodes an alkaline pH-dependent deoxyribonuclease termed alkaline
nuclease. A recombinant UL12 knockout mutant, AN-1, is severely compromised for growth, and analysis of this mutant
suggests that UL12 plays a role in processing complex DNA replication intermediates (R. Martinez, R. T. Sarisky, P. C. Weber,
and S. K. Weller, (1996) J. Virol. 70, 2075–2085). This processing step may be required for the generation of capsids that are
competent for egress from the nucleus to the cytoplasm. In this report, we address the question of whether the AN-1 growth
phenotype is due to the loss of UL12 catalytic activity. We constructed two point mutations in a highly conserved region (motif
II) of UL12 and purified wild-type and mutant enzymes from a baculovirus expression system. Both mutant proteins are stable,
soluble, and competent for correct nuclear localization, suggesting that they have retained an intact global conformation.
Neither mutant protein, however, exhibits exonuclease activity. In order to examine the in vivo effects of these mutations, we
determined whether expression of mutant proteins from amplicon plasmids could complement AN-1. While the wild-type
plasmid complements the growth of the null mutant, neither UL12 mutant can do so. Loss of exonuclease activity therefore
correlates with loss of in vivo function. © 1998 Academic Press
INTRODUCTION
Herpes simplex virus type 1 (HSV-1) is an enveloped
double-stranded DNA virus. The linear genome circu-
larizes upon infection, and this circular template is
replicated into longer-than-unit-length head-to-tail
concatemers. The packaging machinery then cleaves
concatemeric DNA to monomeric units which are
packaged into preassembled capsids. DNA-containing
capsids bud from the nucleus to the cytoplasm, where
they acquire an envelope and mature glycoproteins
(Roizman and Sears, 1996).
HSV-1 encodes an exonuclease termed alkaline nu-
clease, which is the product of the UL12 open reading
frame (Costa et al., 1983). Optimal enzyme activity re-
quires alkaline pH conditions and a divalent metal cat-
ion, but not ATP (Hoffmann and Cheng, 1978; Keir and
Gold, 1963; Strobel-Fidler and Francke, 1980). UL12 ad-
ditionally exhibits an endonuclease activity with a pref-
erence for supercoiled substrates (Hoffmann and Cheng,
1979). Similar exo- and endonucleolytic activities have
been described for UL12 homologs from Epstein–Barr
virus (Baylis et al., 1989, 1991; Lin et al., 1995; Stolzen-
berg and Ooka, 1990), bovine herpesvirus type 1 (Chung
and Hsu, 1997), pseudorabies virus (Hsiang et al., 1996),
and human cytomegalovirus (HCMV) (Sheaffer et al.,
1997). The HSV-1 and HCMV enzymes degrade both
single- and double-stranded DNA in the 59–39 direction
(Knopf and Weisshart, 1990; Sheaffer et al., 1997). Alka-
line nuclease degrades RNA poorly, if at all (Knopf and
Weisshart, 1990; Morrison and Keir, 1968). Despite these
and other biochemical analyses, the role of alkaline
nuclease in vivo remains unclear.
A viral mutant lacking most of the UL12 coding region,
AN-1, has provided some insight into the in vivo role of
alkaline nuclease (Weller et al., 1990). AN-1 is severely
compromised for overall growth and produces infectious
virions at only 0.1–1% the level of wild type. Other mu-
tants such as a UL12 amber mutant (Patel et al., 1996)
and a PRV UL12 insertion mutant (deWind et al., 1994)
display a similar phenotype. UL12 therefore plays an
important role in the viral life cycle. AN-1 synthesizes
wild-type levels of viral DNA, suggesting that UL12 plays
little or no role in DNA replication per se. In addition,
AN-1 infection produces near-wild type levels of nuclear
encapsidated viral genomes, as measured by resistance
to staphylococcal nuclease (SN) (Shao et al., 1993). UL12
therefore plays no essential role in either site-specific
terminal cleavage events or packaging of the cleaved
genome into preassembled nuclear capsids.
The AN-1 phenotype is manifested at the point of
capsid egress from the nucleus. Cells infected with
wild-type virus produce cytoplasmic, as well as nu-
clear, DNA-containing capsids. Cells infected with
AN-1, however, produce only nuclear SN-resistant
DNA; no DNA-containing capsids can be detected
from cytoplasmic fractions (Shao et al., 1993). Further-
more, cells infected with AN-1 accumulate increased
numbers of A capsids (Shao et al., 1993), which pre-
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sumably reflect abortive packaging events (reviewed
in Steven and Spear, 1997). We have proposed that
alkaline nuclease plays a role in the production of
stable DNA-containing capsids which are competent
for egress from the nucleus (Shao et al., 1993). This
model would explain both the failure of DNA-contain-
ing capsids to reach the cytoplasm and the accumu-
lation of higher than normal levels of A capsids.
To address possible reasons for the failure to produce
competent DNA containing capsids, we examined the
structure of replicating DNA in wild-type and AN-1-in-
fected cells by pulsed-field gel electrophoresis (PFGE)
(Martinez et al., 1996a). Wild-type DNA replication inter-
mediates cannot migrate in a pulsed-field gel, which can
normally resolve linear molecules up to 5 Mb in size
(Bataille and Epstein, 1994; Deshmane et al., 1995; Mar-
tinez et al., 1996a; Severini et al., 1994; Zhang et al., 1994).
Although restriction enzymes that cut once per genome
length can release some monomer length linear mole-
cules into the gel, a majority of replicating DNA remains
in the well (at the gel origin). This result suggests that
replicating DNA adopts a complex structure which pre-
sumably must be resolved into linear concatemers prior
to encapsidation. In cells infected with AN-1, however,
cleavage of replicating DNA with a single cutting enzyme
does not release discrete monomeric genomes, sug-
gesting that replicating DNA is even more complex than
in cells infected with wild-type virus (Martinez et al.,
1996a). We have proposed that alkaline nuclease is re-
quired for a genome maturation step, ‘‘processing’’ this
complex DNA to a form suitable for encapsidation. Ge-
nomes which are cleaved and packaged in the absence
of functional alkaline nuclease may retain some level of
complexity, such as small branches or other modifica-
tions, and capsids containing these complex unit length
molecules would then be unstable and unable to egress
from the nucleus (Martinez et al., 1996a; Weller, 1995).
In this report, we address the question of whether
the AN-1 growth phenotype is due to the loss of UL12
catalytic activity. We show that the substitution of
highly conserved amino acid residues in motif II of
UL12 results in a loss of exonuclease activity without
altering stability or intracellular localization. In order to
test in vivo function of these mutations, we used the
method of Berthomme et al. (1996) in which viral genes
are cloned into an amplicon vector (containing an
HSV-1 origin and packaging sequences) and used to
complement the growth of a null mutant virus. In this
study, amplicon plasmids expressing wild-type or mu-
tant forms of the UL12 gene were tested for their ability
to complement AN-1. By this measure, loss of exonu-
clease activity correlates with loss of in vivo function,
suggesting that the exonuclease activity itself is re-
quired for productive infection.
RESULTS
Construction of mutant UL12 genes
The unusual phenotype of AN-1 prompted us to ask
whether its growth defects were due to loss of nuclease
catalytic activity or loss of some as yet undetected func-
tion of UL12 which is separable from its nucleolytic
activity. For instance, it is possible that in addition to a
role in processing viral genomes, alkaline nuclease
plays a structural role in stabilizing DNA-containing cap-
sids for egress from the nucleus. Our objective was to
create subtle mutations in the UL12 gene which would
alter exo activity without altering global conformation or
other functions of the protein. The predicted protein se-
quence was analyzed for resemblance to other known
nucleases. UL12, however, shows no homology to any
nonviral exonuclease. We therefore examined the re-
gions of UL12 that are highly conserved among herpes-
virus homologs and hypothesized that the most highly
conserved amino acids are those required for catalytic
activity. Alkaline nuclease shares seven regions of ho-
mology among herpesviruses, originally described by
Glenda Moore (personal communication) and reported in
Martinez et al. (1996b). The amino acids constituting
each motif are shown in Fig. 1A. Baculoviruses also
encode a homolog of this protein (Ahrens et al., 1997;
Ayres et al., 1994; Poloumienko and Krell, 1996); however,
only motifs I–IV are present in these homologs.
Two mutations were constructed in motif II, as it ap-
pears to be one of the most highly conserved regions
(Fig. 1B). Within this motif, the C-terminal 5 amino acids
(336-GASLD-340) represent the most well-conserved
cluster. Asp340 is an absolutely conserved amino acid,
and aspartic acid residues are required for metal binding
in some endo- and exonucleases (Kovall and Matthews,
1997); Asp340 was therefore chosen for alteration, and a
conservative substitution to a glutamic acid was made
(designated D340E). Nearby, Gly336 and Ser338 are ab-
solutely conserved among 16 herpesvirus homologs. We
generated a more severe 2-amino-acid substitution
(G336A/S338A), and this mutation was termed G336A/
S338A (Fig. 1B).
Stability of mutant proteins
Mutations can result in proteins that are insoluble or
unstable or with radically altered three-dimensional con-
formations. In order to determine whether the two UL12
mutations affect stability of the protein, mutant and wild-
type genes were cloned downstream of the strong CMV
promoter and transfected into Vero cells. Transfected cell
extracts were subjected to sodium dodecyl sulfate–poly-
acrylamide gel electrophoresis (SDS–PAGE) and immu-
noblot analysis as described under Materials and Meth-
ods (Fig. 2a). The 85-kDa UL12 protein is expressed at
similar levels in cells transfected with constructs ex-
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FIG. 1. The seven conserved motifs of alkaline nuclease. (A) The top line shows the seven conserved motifs of herpesvirus alkaline nuclease
homologs. Motifs I, III, IV, V, VI, and VII are expanded to show the conserved residues within each motif. Lineups were generated with PILEUP, a
component of the GCG program [Wisconsin Package Version 9.1, Genetics Computer Group (GCG), Madison, Wisconsin]. Consensus regions were
generated with the PRETTY program; amino acids conserved among at least nine UL12 homologs are capitalized and considered consensus. Only
the alpha-herpesvirus homologs are shown. (B) Motif II is expanded to show conserved residues within this region. The bottom two lines show the
engineered mutations, with altered amino acids underlined. Viruses are abbreviated as follows: HSV1, herpes simplex virus type 1 (McGeoch et al.,
1988); HSV2, herpes simplex virus type 2 (Draper et al., 1986); EHV, equine herpesvirus type 1 (Telford et al., 1992); PRV, pseudorabies virus (Dijkstra
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pressing wild-type or mutant versions of UL12. A faster
migrating band corresponding to an 81-kDa form of UL12
is occasionally seen in cells transfected with wild-type
(Martinez et al., 1996b) and mutant versions of UL12. In
Fig. 2a, this faster migrating band is only seen in lane 2;
however, in other experiments it can be detected in
extracts from cells transfected with mutant versions as
well (data not shown). In summary, the introduced muta-
tions do not appear to grossly affect the stability of the
UL12 protein. The purification of both mutant proteins
from recombinant baculovirus-infected insect cells (dis-
cussed below) additionally shows that they are stable
and soluble.
Alkaline nuclease is localized diffusely throughout the
nucleus (Banks et al., 1983, 1985; Randall and Din-
woodie, 1986; Thomas et al., 1988, 1992), and it is pos-
sible that subtle mutations could influence its localiza-
tion pattern. For instance, conformational changes may
knock out the ability of the nuclear transport machinery
to interact with UL12. Wild-type UL12, expressed by
transfection, adopts the same diffuse nuclear localization
as seen during wild-type infection (Fig. 2b). This indi-
cates that UL12 contains its own nuclear localization
signal. Only rarely was UL12 seen throughout the entire
cell (Fig. 2b, top right), and this may reflect overexpres-
sion of UL12 in transfected cells. Transfection of mutants
G336A/S338A and D340E shows that neither mutation
influences intracellular localization (Fig. 2b). The mutant
proteins have therefore retained the ability to localize
appropriately, and this further suggests that they retain
an intact global conformation.
Enzymatic characterization of mutant proteins
In order to examine UL12 biochemical activity, it was
necessary to obtain purified UL12 protein. An Esche-
richia coli expression/purification procedure has been
published (Bronstein and Weber, 1996), but it involves a
lengthy resolubilization of insoluble protein. In addition,
expression of the EBV alkaline nuclease in baculovirus is
100-fold more efficient than E. coli expression of the
same protein (Baylis et al., 1991). UL12 was therefore
expressed in a recombinant baculovirus system and
purified as described under Materials and Methods. Our
original purification procedure, termed scheme 1, re-
sulted in wild-type UL12 that was greater than 95% pure
as judged by Coomassie staining. Wild-type UL12 is
stable and soluble, and its activity is similar to that
purified from E. coli and from infected cells (Banks et al.,
1983; Bronstein and Weber, 1996; Hoffmann and Cheng,
1978; Morrison and Keir, 1968; Strobel-Fidler and
Francke, 1980). Notably, two peaks of exonuclease ac-
tivity eluted in the fractions from the SP–Sepharose col-
umn; one contained UL12 (which was subsequently pu-
rified) and one did not. This non-UL12 exonuclease ac-
tivity may represent the baculovirus UL12 homolog,
which is predicted to encode a 48-kDa protein (Ayres et
al., 1994).
Unexpectedly, purification scheme 1 was not satisfac-
tory for the UL12 motif II mutant proteins. Although the
mutant proteins eluted in the same fractions as wild-type
UL12, more background proteins eluted with them. Minor
conformational differences may have caused the mutant
proteins to weakly associate with other proteins. We
therefore developed a new purification scheme, scheme
2, which produced wild-type and mutant proteins that
were stable, soluble, and greater than 95% pure as
judged by Coomassie staining (Fig. 3). All experiments in
this report were performed with protein purified by
scheme 2. As a control for contaminating activities, an
extract of insect cells infected with wild-type baculovirus
(expressing no recombinant proteins) was subjected to
scheme 2 (Fig. 3, lane 4).
To test for exonuclease activity, wild-type and mutant
proteins were incubated with 3H-labeled E.coli single-
stranded DNA, and the release of acid-soluble nucleo-
tides was measured. Neither D340E nor G336A/S338A
exhibits exonuclease activity on this substrate (Fig. 4).
The same results were obtained when 3H double-
stranded DNA was used (data not shown). To test for
endonuclease activity, we incubated the mutant proteins
with a closed circular supercoiled plasmid (Fig. 5). Wild-
type UL12 nicks this substrate, then degrades the nicked
form (Fig. 5, lane 3). D340E retains the ability to nick a
supercoiled substrate (Fig. 5, lane 4), suggesting that its
endonuclease activity is intact, although reduced some-
what from wild-type levels. The nicked form of the plas-
mid accumulates because this protein has no exonucle-
ase activity (as in Fig. 4). G336A/S338A appears to ex-
hibit little or no endonuclease activity (Fig. 5, lane 5). In
order to control for the possibility that this nicking activity
was simply a background endonuclease copurifying with
UL12, we purified an extract from vector-only (wild-type
baculovirus) infected insect cells. Lane 6 of Fig. 5 shows
that this extract exhibits no endonuclease activity. While
et al., 1996); BHV1, bovine herpesvirus type 1 (Vlcek et al., 1995); VZV, Varicella-zoster virus (Davison and Scott, 1986); HVS, herpesvirus saimiri
(Albrecht et al., 1992); KSHV, Kaposi’s-sarcoma-associated herpesvirus or human herpesvirus type 8 (Russo et al., 1996); EHV2, equine herpesvirus
type 2 (Telford et al., 1992); GHV68, murine gamma herpesvirus 68 (Virgin et al., 1997); AHV1, alcelaphine herpes virus type 1 (Ensser et al., 1997); EBV,
Epstein–Barr virus (Baer et al., 1984); HHV6, human herpesvirus type 6 (Gompels et al., 1995); HHV7, human herpesvirus type 7 (Nicholas, 1996);
HCMV, human cytomegalovirus (Bankier et al., 1991); MCMV, murine cytomegalovirus (Rawlinson et al., 1996); OpNPV, Orgyia pseudotsugata
polyhedrosis virus (Ahrens et al., 1997); AcNPV, Autographa californica nuclear polyhedrosis virus (Ayres et al., 1994); CfNPV, Choristoneura fumiferana
nuclear polyhedrosis virus (Poloumienko and Krell, 1996).
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it remains a formal possibility that a background endo-
nuclease copurifies with UL12, the most likely explana-
tion for these results is that the endo activity observed is
encoded by UL12 itself. The band representing the open
circular form of the plasmid appears somewhat fainter in
the vector-only lane than in the no enzyme lane (Fig. 5,
FIG. 2. Transient transfection of Vero cells with plasmids expressing wild-type and mutant proteins. (a) Western blot. Vero cells were transfected
with plasmids pF19-CMV (expression vector alone), pF19-AK (wild-type UL12), pF19-AK(G336A/S338A), or pF19-AK(D340E). Cells were harvested 24 h
posttransfection, lysed in 13 SDS–PAGE loading buffer, and loaded onto an 8% SDS–polyacrylamide gel. Following electrophoresis, proteins were
transferred onto nitrocellulose and UL12 was detected with polyclonal antibody BWp12. Molecular weight markers (10-kDa protein ladder, GIBCO) are
shown on the left. The faster-migrating band just below UL12 may represent a proteolytic breakdown product (Martinez et al., 1996b). (b) Indirect
immunofluorescence. Vero cells were transfected with one of four plasmids: pF19-CMV, pF19-AK, pF19-AK(G336A/S338A), or pF19-AK(D340E). UL12
was detected with monoclonal antibody Q1. Bar, 10 mm.
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compare lanes 2 and 6). The vector-only extract may
contain a small amount of background exonuclease ac-
tivity; however, this activity could not be detected by the
more quantitative exonuclease assay (Fig. 4). In sum-
mary, one motif II mutant, D340E, retains endonuclease
activity but exhibits no exonuclease activity, whereas
G336A/S338A appears to be defective in both activities.
Construction of recombinant viruses
In order to probe the in vivo effects of mutations in
motif II, we set out to construct recombinant viruses
containing these mutations. The previously isolated null
mutant, AN-1, was constructed by deletion of the UL12
gene and insertion of the LacZ gene; it forms blue
plaques in the presence of X-gal (Weller et al., 1990).
Complementing 6-5 cells were cotransfected with plas-
mids containing the two mutant UL12 genes and AN-1
infectious DNA, and the viral progeny were screened for
clear plaques (viruses that had lost the LacZ gene). Two
independent transfections were performed with each
mutant, and several viral isolates were picked and triple-
plaque-purified. Although Southern blot analysis demon-
strated that four of the G336A/S338A isolates had cor-
rectly incorporated the mutant gene, three G336A/S338A
isolates and one D340E isolate had undergone unusual
recombination events (data not shown). In addition, four
D340E isolates retained the AN-1 genomic pattern, de-
spite the clear plaque phenotype. Western blot analysis
then showed that none of these clear-plaque isolates,
even the ones that appeared correct by Southern blot
analysis, expressed any UL12 protein (data not shown).
We have successfully used a similar marker transfer
protocol to introduce the wild-type UL12 gene, the frame-
shift mutant AN-F1 (Martinez et al., 1996b), and a substi-
tution in Methionine 127 (Goldstein and Weller, unpub-
lished data) into the AN-1 genome. For comparison,
seven out of seven clear plaque isolates of the Methio-
nine 127 mutation had correctly incorporated the muta-
FIG. 4. Mutations in motif II eliminate exonuclease activity. 10 ng of
UL12, D340E, G336A/S338A, or an equivalent amount of vector-only
extract was incubated with 3H-labeled single-stranded DNA as de-
scribed under Materials and Methods. Exonuclease activity was mea-
sured as the release of acid-soluble radioactivity per unit time. The
results of three independent experiments are plotted, with mean and
standard errors shown.
FIG. 5. Mutations in motif II do not eliminate endonuclease activity.
150 ng of each enzyme (UL12, D340E, or G336A/S338A) was added to
62 ng of plasmid pUC18 and incubated for 2 h. Lane 1 shows pUC18
linearized with SacI as a control. Lane 6 includes an equivalent volume
of vector-only extract. The products were subjected to agarose gel
electrophoresis and stained with ethidium bromide. Under these con-
ditions, the open circular (OC) and linear (L) forms of pUC18 migrate at
the same position, and the supercoiled (SC) form migrates faster.
FIG. 3. Purified UL12 mutant proteins. 1 mg each of purified UL12,
D340E, and G336A/S338A were loaded onto an 8% SDS–polyacrylam-
ide gel. Following electrophoresis, the gel was stained with Coomassie
brilliant blue. Lane 4 represents a vector-only cell extract, purified by
the same method as UL12. Little protein was recovered; quantity was
normalized to percentage of total yield. Molecular weight markers are
shown on the left.
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tion and express protein, showing that unusual recom-
bination events are rare during marker transfer experi-
ments such as those performed here. The failure of
recombinant viruses containing the D340E and G336A/
S338A mutations to produce the UL12 protein suggests
that a strong selection exists against expression of these
mutant proteins. Thus, the two mutations may not only
create functionally inactive protein, but in addition the
mutant proteins may be transdominant inhibitors of wild-
type viral growth.
Transient complementation assay
In order to directly examine whether the motif II mu-
tants can complement a null mutant, we performed tran-
sient complementation assays. Previous experiments
have demonstrated that it is difficult to complement UL12
mutants to wild-type levels of virus production, even in
cell lines that express wild-type levels of UL12 (Shao et
al., 1993; Weller et al., 1990). Although the reasons for this
inefficient complementation are not fully understood, the
viral life cycle may be sensitive to altered temporal or
spatial patterns of expression from chromosomal, rather
than viral, copies of the UL12 gene. Complementation by
transient transfection might be expected to support even
less efficient viral growth than would complementing cell
lines, since not all cells are transfected. In order to
maximize the levels of transcomplementation, we took
advantage of the system described by Berthomme et al.
(1996), in which increased levels of transcomplementa-
tion were obtained through the use of amplicon vectors.
Amplicons are plasmids that contain an HSV origin of
replication and a packaging sequence, allowing them to
be replicated by the virus and packaged into defective
viruses (Frenkel et al., 1994). We therefore cloned UL12
and the two motif II mutants into the amplicon vector
pF19-CMV (Hong et al., 1996). Vero cells were transfected
with amplicon plasmids expressing wild-type UL12 and
the two mutant genes, superinfected with the UL12 null
mutant virus AN-1, and progeny virus was harvested. If a
mutant gene is functional, cells transfected with this
gene would be expected to support an increased rate of
virus replication. The results from three independent
experiments are shown in Table 1. The wild-type UL12
plasmid, pF19-AK, consistently complements the null mu-
tant, albeit somewhat inefficiently. In contrast to wild-type
UL12, neither G336A/S338A nor D340E can support
growth above background (Table 1). It appears, then, that
mutations that eliminate exonuclease activity also elim-
inate in vivo function.
In order to extend these results, we took advantage of
the fact that the plasmids used for transient complemen-
tation contained the viral packaging signal and are ex-
pected to be packaged into defective virions. Progeny
virus from AN-1 infection of transfected Vero cells are
expected to contain both helper virus (AN-1) and defec-
tive amplicon genomes [pF19-CMV, pF19-AK, pF19-
AK(G336A/S338A), or pF19-AK(D340E)]. The progeny
from this infection can be used to infect fresh Vero cells
and test the ability of the defective genomes to support
multiple rounds of infection. This may be a more sensi-
tive assay for transcomplementation ability of UL12
genes, as the cumulative effects of multiple rounds of
infection are measured. Vero cells were transfected with
one of the four amplicon plasmids, superinfected with
AN-1, and 1/10 of the viral progeny was used to infect
fresh Vero cells. Viral progeny from this second passage
was harvested 4 or 8 days postinfection and titered on
complementing 6-5 cells. The results are shown in Table
2. The vector-only plasmid, pF19-CMV, could not support
multiple rounds of AN-1 infection on Vero cells, and no
plaque-forming units were recovered. In contrast, the
amplicon that expresses wild-type UL12 (pF19-AK) could
support multiple rounds of infection, generating relatively
high viral titers. Therefore, while examination of one
round of infection (Table 1) demonstrates only a 4-fold
increase in complementation ability of the wild-type UL12
plasmid, examination of multiple rounds demonstrates a
greater than 88,000-fold increase over vector-only. Nei-
ther UL12 mutant could support multiple rounds of infec-
tion, as no plaque-forming units were recovered from
either infection.
Unexpectedly, most of the plaques recovered from the
wild-type UL12 amplicon passage were recombinants.
Forty to ninety percent of the progeny formed clear
plaques rather than blue, suggesting that the wild-type
UL12 gene has recombined into the AN-1 genome and
replaced the LacZ insertion. Our results differ from those
of Berthomme et al. (1996), who recovered few recombi-
nants. The fact that UL12 complements poorly in trans
may have contributed to a selection for wild-type recom-
binants. No recombinants, however, were recovered
from passages with the mutant UL12 genes. Had either
TABLE 1
Transient Complementation of the UL12 Null Mutant Virus AN-1
by UL12 Expression Plasmidsa
Plasmid
Complementation indexb
Expt. 1 Expt. 2 Expt. 3 Mean 6 SE
pF19-CMV 1.0 1.0 1.0 1.0
pF19-AK 6.0 4.0 4.3 4.8 6 0.6
pF19-AK(D340E) 0.4 0.6 1.0 0.7 6 0.2
pF19-AK(G336A/S338A) 0.7 0.8 0.9 0.8 6 0.06
a Vero cells were transfected with the indicated plasmid and super-
infected with AN-1 as described under Materials and Methods. Prog-
eny virus was titered on 6-5 cells. The results from three different
experiments are shown.
b Complementation index (CI) is calculated as PFU of progeny virus
from cultures transfected with the indicated plasmid/PFU of progeny
virus from vector-only (pF19-CMV) transfected cultures.
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D340E or G336A/S338A been competent for AN-1
complementation, progeny virus (recombinant or not)
would still have been isolated at the levels seen with the
wild-type UL12 gene. Therefore, we conclude that neither
UL12 mutant is competent for productive viral infection.
Generation of defective viral stocks
In order to perform additional analyses of the proper-
ties of the mutant proteins, it was important to obtain a
stock of virus capable of expressing mutant proteins.
Defective viral stocks were therefore propagated on the
complementing cell line. Complementing 6-5 cells were
transfected with pF19-CMV, pF19-AK, pF19-AK(G336A/
S338A), and pF19-AK(D340E). Transfected cells were su-
perinfected with AN-1, and progeny virus (passage 0)
was used to infect fresh 6-5 cells. Viral progeny from this
passage (passage 1) are expected to contain defective
amplicon molecules as well as AN-1 genomes. If the
mutant UL12 genes are functional, then amplicon mole-
cules expressing these mutant proteins will support
growth of the AN-1 null mutant on Vero cells. Vero cells
were infected with the four amplicon stocks and exam-
ined for protein expression, intracellular localization, and
viral growth at the same time. Figure 6 shows that the
defective viral stocks express protein; lanes 2 and 6
show that the wild-type virus (KOS) and the wild-type
UL12 amplicon express similar levels of UL12. Lanes 7
and 8 show that the mutant UL12 amplicons also express
protein. Figure 7 shows that the mutant proteins are able
to localize to the nucleus in the context of a viral infection
and adopt the same diffuse localization as wild-type
UL12. Figure 8 shows a growth curve of the four defec-
tive viral stocks on Vero cells, in which progeny were
titered on complementing 6-5 cells. The stock that ex-
presses wild-type UL12 (pF19-AK) produces 10-fold more
virus than the stock that expresses no UL12 (pF19-CMV,
the vector alone). Notably, it does not grow to the levels
of wild-type KOS; as described above, this probably re-
flects the poor ability of wild-type UL12 to complement in
trans. In order to determine whether the UL12 motif II
mutants could support AN-1 growth as well as wild-type
UL12, Vero cells were infected with the mutant defective
stocks [pF19-AK(D340E) or pF19-AK(G336A/S338A)].
These stocks produce similar titers to the vector alone
(Fig. 8). Thus, when the mutant UL12 proteins are ex-
pressed by infection, rather than by transfection, they
cannot support AN-1 viral growth. The observation that
defective mutant stocks express wild-type levels of UL12
protein which localizes appropriately to the nucleus fur-
ther supports the contention that the mutations in motif II
do not alter the global conformation of the protein.
DISCUSSION
We report the construction of two mutations (D340E
and G336A/S338A) in highly conserved residues within
motif II of the HSV-1 UL12 gene. Wild-type and mutant
proteins were expressed in insect cells following infec-
tion with recombinant baculoviruses and in mammalian
cells by transient transfection. Wild-type and mutant pro-
teins were purified to 95% homogeneity from infected
TABLE 2
Growth of Vero-Passaged Defective Viral Progenya
Amplicon plasmid
4 days
postinfection
8 days
postinfection
Titer CIb Titer CIb
pF19-CMV ,10 ,10
pF19-AK 8.8 3 105 .88,000 2.0 3 107 .2,000,000
pF19-AK (D340E) ,10 ;1 ,10 ;1
pF19-AK (G336A/S338A) ,10 ;1 ,10 ;1
a Vero cells were transfected with indicated plasmid and superin-
fected with AN-1 as described under Materials and Methods. Progeny
virus was harvested and used to infect fresh Vero cells. Four or 8 days
postinfection, progeny virus was harvested and titered on complement-
ing 6-5 cells. Titer is expressed as PFU/ml.
b Complementation index (CI) is calculated as PFU of progeny virus
from cultures infected with the indicated defective progeny/PFU of
progeny virus from vector-only defective viral progeny.
FIG. 6. Defective viral stocks express UL12. Vero cells were infected
with no virus (mock), wild-type KOS, UL12 null mutant AN-1, UL12
frameshift mutant AN-F1, vector-only (pF19-CMV) stock, wild-type UL12
(pF19-AK) stock, or either of two UL12 mutant defective stocks [pF19-
AK(G336A/S338A) or pF19-AK(D340E)], at an MOI of 1 PFU/cell. Cells
were harvested 12 h postinfection, boiled in 13 SDS–PAGE loading
buffer, and run on 8% SDS–PAGE. The gel was blotted onto nitrocellu-
lose paper and hybridized with anti-UL12 antibody BWp12. A prestained
protein ladder (GIBCO) was used to mark molecular weights.
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insect cells, and while the wild-type protein exhibited
both endo- and exonuclease activities, both the D340E
and the G336A/S338A mutations eliminate exonuclease
activity. D340E appears to retain endonuclease activity,
whereas the G336A/S338A mutation is significantly im-
paired as an endonuclease. Mutations in motif II do not
appear to drastically alter the global stability of the alka-
line nuclease as judged by stable protein expression in
both expression systems, the partial retention of endo-
nuclease activity in at least one of the mutants, and the
ability of both proteins to localize to the nucleus of
transfected Vero cells. We conclude that motif II plays an
important role in the exonuclease activity of the alkaline
nuclease. Furthermore, the inability of either D340E or
G336A/S338A to complement the growth of a null mutant
in alkaline nuclease, AN-1, indicates that loss of exonu-
clease activity correlates well with the loss of in vivo
function.
Comparison of alkaline nuclease homologs from sev-
eral different herpesviruses has revealed the presence
of seven conserved motifs and has also suggested that
the N-terminus of the HSV-1 and HSV-2 UL12 may not
play a role in its enzymatic activity, since the HSV-1 and
HSV-2 enzymes both contain approximately 100 N-termi-
nal amino acids that are not present in the other ho-
mologs. This suggestion has been supported by the
results of Bronstein et al. (1997) which show that an
N-terminally truncated version of UL12, designated
UL12.5, retains endo- and exonuclease activities. In the
only other reported structure–function analysis of an al-
kaline nuclease homolog, mutations in the N-terminus of
the EBV alkaline nuclease knock out exonuclease activ-
ity (Lin et al., 1994); however, these mutations are in a
region outside the seven conserved motifs that is not
well conserved among the herpesvirus homologs. These
inactivating residues may therefore be EBV-specific. It is
interesting to note that baculoviruses encode an open
reading frame with homology to UL12 in motifs I–IV.
Since it is not clear whether these viruses actually en-
code a protein with enzymatic properties similar to the
herpesvirus alkaline nuclease, it is not possible to pre-
dict whether the endo- and exonuclease activities are
likely to reside within motifs I–IV or whether all seven
motifs are essential for enzymatic activity. Further ge-
netic analyses will be required to determine which motifs
in addition to motif II are important for enzymatic activi-
ties of this enzyme.
The ability of the HSV-1 UL12 protein to carry out
both endo- and exonuclease activities raises the ques-
tion of whether both activities are performed by sep-
arable domains of the UL12 gene. It also remains a
formal possibility that the endonuclease activity is not
an inherent activity of the UL12 gene product but
rather represents a contaminating nuclease which co-
purifies with the UL12 protein. The fact that UL12
expressed in E. coli, in insect cells, and in infected
mammalian cells exhibits both endo- and exonuclease
activities makes this latter possibility less likely. We
FIG. 7. Mutations in UL12 motif II do not affect nuclear localization in the context of viral infection. Vero cells were infected with one of four
amplicon-supported AN-1 viral stocks: pF19-CMV, pF19-AK, pF19-AK(G336A/S338A), or pF19-AK(D340E). Five hours postinfection, UL12 was detected
with monoclonal antibody Q1. Bar, 10 mm.
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and others have observed that endonuclease activity
appears only under conditions of vast excess of the
UL12 protein; this result may suggest that the ob-
served endonuclease activity represents a somewhat
artifactual activity which can be observed in the test
tube but plays little or no role in vivo. In this study we
report that one of the motif II mutations apparently
abolishes both endo- and exonucleolytic activities
while the other mutation abolishes exonuclease activ-
ity while retaining endo activity. The fact that both
mutants are defective in vivo strongly suggests that it
is the exonuclease activity which correlates with in
vivo function of the UL12 protein. Thus the endonucle-
ase activity of UL12 may not be important in vivo;
however, further genetic analysis will be necessary to
determine whether an exo1endo2 mutation can be
isolated and whether such a mutation will be compe-
tent for in vivo function.
In this paper, we also report that it was not possible to
isolate recombinant viruses bearing the motif II muta-
tions despite the fact that other mutations have been
easily transferred into the HSV-1 genome by marker
transfer. One possible explanation for our failure to in-
troduce the motif mutations into the viral genome is that
the constructs used have affected overlapping or anti-
sense transcripts in this region. Alternatively, the motif II
mutations may be exerting a transdominant inhibitory
effect, making it impossible to recover the desired re-
combinant viruses. For instance, mutant versions of UL12
may still participate in protein–protein interactions or in
the formation of UL12 dimers or higher order multimers.
Further experiments, such as those described previously
for transdominant mutations in the UL9 gene (Malik and
Weller, 1996), will be necessary to directly address this
question.
To address the ability of the mutant proteins to func-
tion in vivo, we turned to the amplicon system originally
developed by Berthomme et al. (1996). In vivo comple-
mentation assays were performed in three ways: tran-
sient complementation, production of defective amplicon
stocks which were passaged on Vero cells, and produc-
tion of defective amplicon stocks which were passaged
on a complementing cell line. The third assay system
facilitates the generation of viral stocks that express
nonfunctional proteins and allowed us to examine the
stability, localization, and function of the motif II mutants
in the context of a viral infection, rather than by transfec-
tion. This extension of the amplicon system may be
useful for the genetic analyses of other mutant viral
genes which are difficult to introduce directly into viral
genomes.
Another observation made in this paper concerns the
somewhat unusual intracellular localization of the UL12
protein. It has been known for some time that UL12 is
found in the nucleus of infected cells in a diffuse staining
pattern (Puvion-Dutilleul and Pichard, 1986; Randall and
Dinwoodie, 1986; Thomas et al., 1988, 1992). DNA repli-
cation occurs in the nucleus of infected cells in large
FIG. 8. Growth of defective viral stocks. Vero cells were mock-infected, KOS-infected, or infected at an MOI of 1 PFU per cell with passage 1 (p1)
of the following amplicon stocks: pF19-CMV (vector only), pF19-AK (wild-type UL12), pF19-AK(G336A/S338A), pF19-AK(D340E). Cells were harvested
either immediately following 1 h adsorption (0 hpi) or at various times postinfection. Viral progeny was titered on complementing 6-5 cells.
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globular nuclear domains called replication compart-
ments, originally defined on the basis of staining pat-
terns of the single-stranded DNA binding protein (UL29,
ICP8) in infected cells (de Bruyn-Kops and Knipe, 1988;
Quinlan et al., 1984). If UL12 and UL29 interact with each
other as has been reported (Thomas et al., 1988, 1992), it
might be expected that they would colocalize within the
nucleus. However, despite early reports that UL12 may
be localized preferentially in replication compartments
(Thomas et al., 1992), we have not been able to repeat
these findings. In fact several lines of evidence suggest
that UL29 and UL12 have very different interactions with
components of the nucleus. For instance, most biochem-
ical fractionation procedures in which UL12 is purified
from infected cells utilize cytoplasmic rather than nuclear
fractions, suggesting that UL12 is only weakly associ-
ated with the nucleus (Hoffmann and Cheng, 1979; Stro-
bel-Fidler and Francke, 1980). Furthermore, while UL29
appears to associate with components of the nuclear
matrix (Quinlan et al., 1984), UL12 appears to be present
in the soluble nuclear milieu at least at early times during
infection (Turco and Pignatti, 1988; A. Hopkins, J. Gold-
stein, and S. Weller, unpublished results). Finally, elec-
tron microscopy shows that while UL12 is present in
electron-dense bodies (Puvion-Dutilleul and Pichard,
1986), UL29 is excluded from them (Puvion-Dutilleul et
al., 1985). It thus appears that UL12 and UL29 are subject
to quite different compartmental restrictions, and inter-
actions between the two may be transient. Taken to-
gether, these results imply that UL12 may act at a differ-
ent stage of the viral life cycle than UL29 and are con-
sistent with the genetic data suggesting that it is not
required for DNA replication or initiation of recombina-
tion. UL12 may act only on DNA molecules which are not
matrix-bound and are perhaps in transit from the DNA
replication machinery to the cleavage and packaging
machinery.
Despite a great deal of study, the in vivo function of
the HSV-1 alkaline nuclease remains uncertain. Exo-
nucleases are known to be required for DNA replica-
tion, DNA recombination, and DNA repair in a number
of biological systems (Fraser, 1994; Lieber, 1997); how-
ever, UL12 is not required for the initiation of replica-
tion or recombination during herpesvirus infection
(Francke and Garrett, 1982; Martinez et al., 1996a;
Weller et al., 1990). Some models of UL12 function
have focused on its endonucleolytic activity; however,
our data indicate that it is in fact the exonuclease
activity which correlates with in vivo function of the
nuclease. We cannot, however, rule out the possibility
that UL12 plays an additional role later in the viral life
cycle. The data presented in this paper suggest that
the phenotype of mutants lacking UL12 can be ex-
plained by the inability to ‘‘process’’ replicating DNA
appropriately. We have suggested that UL12 is in-
volved in a postreplication, postrecombination pro-
cessing step, resolving complex replication intermedi-
ates into a linear form for the packaging process
(Martinez et al., 1996a). This activity may be a novel
type of repair, converting damaged (or noncompetent)
DNA to a form competent for stable encapsidation. A
role for exonucleases in secondary structure repair
has been proposed for other systems (Fraser, 1994),
and the UL12 exonuclease may perform an analogous
role during herpesvirus replication.
MATERIALS AND METHODS
Cells and viruses
Spodoptera frugiperda (Sf9) cells were grown in
Grace’s insect medium (GIBCO Life Technologies, Inc.,
Gaithersburg, MD) containing 10% (v/v) fetal calf serum
(GIBCO), 0.1 mg/ml streptomycin, and 100 units/ml pen-
icillin (Sigma, St. Louis, MO). Viral stocks were amplified
in Sf9 cells for 6 days at 27°C. Stocks were titered by
determining the volume of viral stock which gave the
maximum level of recombinant protein expression on
1 3 106 Sf9 cells at 50 h postinfection. Stocks were
stored in the dark at 4°C. African green monkey kidney
cells (Vero; American Type Culture Collection, Rockville,
MD) were propagated as described previously (Weller et
al., 1983). The 6-5 and S22 cell lines, which are permis-
sive for UL12 mutants, were previously described (Car-
michael et al., 1988; Shao et al., 1993). The KOS strain of
HSV-1 was used as the wild-type virus. The UL12 null
mutant virus, AN-1, a 917-bp deletion/LacZ insertion, was
described in Weller et al. (1990). The UL122UL12.51
frameshift virus, AN-F1, was described in Martinez et al.,
(1996b). Growth of viral stocks was measured as de-
scribed in Shao et al. (1993) with some modifications.
Tissue culture dishes (35 mm) containing 5 3 105 Vero
cells each were infected at an MOI of 1 PFU per cell.
Viral progeny were harvested and titered on comple-
menting 6-5 cells.
Plasmids
The plasmid pUC119-AK (referred to as pAK), contain-
ing the UL12 gene and its promoter, was described in
Martinez et al. (1996b). The amplicon plasmid pF19-CMV
contains the HSV-1 oris sequence and the ‘‘a’’ sequence
(Hong et al., 1996) and was generously provided by Ann
D. Kwong. Plasmid pAK-B1 contains a BamHI site in-
serted upstream of the UL12 open reading frame and
was constructed as follows. The plasmid pAK was used
as the template for PCR with primers BamKT3Ctrl (59-
TCCCCCCACGTCGGATCCACCATGGAGTCCACGGTA-39)
and Back (59-GTAAAACCCCATGAG-39) [The inserted
BamHI site is highlighted in boldface, and an en-
hanced Kozak consensus sequence (Kozak, 1986) is
underlined]. This 650-bp product was digested with
BamHI and MscI, and the 480-bp product subcloned
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into pSL301 to generate plasmid B1. Plasmids pAK and
B1 were both digested with EcoRI and HindIII, and the
0.3-kb B1 fragment (containing the new BamHI site)
was inserted into pAK to form pAK-B1. This is not an
expression vector, as promoter sequences have been
lost, but rather a convenient cloning vehicle with the
intact UL12 open reading frame flanked by BamHI
sites. In order to generate pF19-AK, UL12 was excised
from pAK-B1 with BamHI and inserted into the BglII
site of vector pF19-CMV. To place a BamHI site up-
stream of each UL12 mutant open reading frame (mu-
tant construction is described below), XhoI–NcoI frag-
ments from pAK(IIAla) and pAK(IIGlu) were subcloned
into pAK-B1 to generate pAK-B1(IIAla) and pAK-
B1(IIGlu). Bacmids (baculovirus genomes containing
the alkaline nuclease gene) were generated by exci-
sion of the mutant UL12 genes from pAK-B1(IIAla) and
pAK-B1(IIGlu) with BamHI and ligation into the pFast-
Bac1 baculovirus transfer vector (Bac-to-Bac recombi-
nant baculovirus kit; Life Technologies, Inc.), generat-
ing IIAla-Fastbac and IIGlu-Fastbac. The mutant UL12
genes were cut out of plasmids IIAla-Fastbac and
IIGlu-Fastbac with BamHI and inserted into the BglII
site of pF19-CMV, generating pF19-AK(D340E) [also
termed pF19-AK(IIGlu)] and pF19-AK(G336A/S338A)
[also termed pF19-AK(IIAla)], respectively. All plasmids
were propagated in E. coli strain DH5a by standard
procedures (Ausubel et al., 1997).
Construction of point mutations
Mutations were constructed by two-step PCR (Ausubel
et al., 1997). Primers were obtained from National Bio-
sciences, Inc (Plymouth, MN). The outside primers were
AlkA (59-CCATCGGTCCCCTCT-39) and GluB (59-GATC-
CCGTTACTATCACC-39). The mutagenic primers were as
follows, with the mutated nucleotides bold and under-
lined: AlaC (59-AATATCCAGTGCGGCCGCGACCATCCC-
39), AlaD (59-GGGATGGTCGCGGCCGCACTGGATATT-39),
GluC (59-AGAATTTCCAGGGAC-39), and GluD (59-CTG-
GAAATTCTCGT-39). G336A/S338A was constructed with
the AlaC and AlaD primers, and D340E was constructed
with the GluC and GluD primers. The mutated PCR prod-
ucts were digested with XhoI and NcoI, and the 0.6-kb
fragments subcloned back into pUC119-AK. The clones
were confirmed by the restriction sites introduced: NotI
for the D340E mutation and ApoI for the G336A/S338A
mutation. Sequencing of the 0.6-kb region confirmed that
no spontaneous mutations were introduced by PCR. The
D340E mutant plasmid was designated pAK(IIGlu), and
the G336A/S338A mutant was designated pAK(IIAla).
Protein expression and purification
The UL12-expressing baculovirus stock, AcAN, was
kindly provided by Fred L. Homa (Pharmacia & Upjohn,
Kalamazoo, MI). The UL12 mutant-expressing baculo-
virus stocks, AcAN(IIAla) and AcAN(IIGlu), were gen-
erated with bacmids IIAla-Fastbac and IIGlu-Fastbac,
respectively, as described in Graves-Woodward et al.
(1997).
One liter of Sf9 cells was grown in suspension at 27°C
in Grace’s insect medium containing 10% (v/v) fetal calf
serum, 0.1 mg/ml streptomycin, 100 units/ml penicillin,
and 0.1% (v/v) Pleuronic F-68 (GIBCO Life Technologies)
in a 6-liter flask (100 rpm). When the cell density reached
1 3 106 cells/ml, the cells were centrifuged in 250-ml
bottles for 10 min at 300 g in a Sorvall GSA rotor. The
cells were infected in 100 ml of medium plus virus inoc-
ulum for 1 h. The infected cells were then added back to
a 6-liter flask with 900 ml fresh medium, and incubated
for 50 h at 27°C.
Cells were pelleted, washed with 13 phosphate-buff-
ered saline (PBS; 137 mM NaCl, 2.7 mM KCl, 4.3 mM
Na2HPO4z7H2O, 1.4 mM KH2PO4, pH 7.3), and repelleted.
Typical cell yield was approximately 5 g. Cells were
frozen at 270°C, thawed at 37°C, and resuspended in 40
ml cold Buffer A (10 mM Tris–HCl, pH 7.5, 1 mM MgCl2,
0.5 mM dithiothreitol, 80 mM KCl, 0.2% NP-40). At this
step, and for each subsequent step, the following pro-
tease inhibitors were added: 13 mg/ml aprotinin, 7 mg/ml
leupeptin, 7 mg/ml pepstatin A, 1 mM phenylmethylsul-
fonyl fluoride. After 10 min swelling on ice, cells were
dounced by 10–20 strokes with a type B pestle. Nuclei
were pelleted by centrifugation at 10,000 g in a Sorvall
GSA rotor. The cytosolic extract was set aside, the nuclei
resuspended in 40 ml Buffer A, and the nuclei repelleted.
Both supernatants were combined for an 80-ml cytosolic
extract and clarified at 100,000 g in an SW28 rotor. The
UL12-containing extract was precipitated with 8.5 g am-
monium sulfate, for a saturation of 20%, for 45 min at
10°C. The precipitate was removed by centrifugation at
17,000 g in a Sorvall SS-34 rotor for 30 min. The super-
nate was then precipitated with 23 g ammonium sulfate,
bringing the saturation up to 55%. After 1 h at 10°C, the
extract was centrifuged at 17,000 g for 30 min, and the
supernatant was removed and centrifuged again, to pre-
cipitate all remaining protein. The two pellets were com-
bined and resuspended in 5 ml Buffer B [20 mM potas-
sium phosphate, pH 8, 20% glycerol, 5 mM b-mercapto-
ethanol (BME)]. This pelleted fraction was dialyzed
overnight against Buffer B and clarified by centrifugation
at 17,000 g.
The cleared UL12-containing extract was loaded onto
a 20-ml HiLoad 16/10 SP–Sepharose anion-exchange
column (Pharmacia, Piscataway, NJ) that had been equil-
ibrated with Buffer B. Following a 1-column wash, UL12
was eluted with a 100-ml gradient of Buffer B to Buffer C
(same as Buffer B but with 0.5 M potassium phosphate,
pH 8). UL12-containing fractions typically eluted between
0.1 and 0.2 M salt. Fractions were pooled, spin-concen-
trated with 10K Microsep Microconcentrators (Filtron,
Northborough, MA) according to the manufacturer’s in-
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structions, and diluted into Buffer A1 (10% glycerol, 20
mM potassium phosphate, 5 mM BME).
Following Sepharose chromatography, we used two
separate purification schemes (see Results). Scheme 1:
Pooled fractions from the Sepharose column were
loaded onto a Superose 12 gel-filtration column (Phar-
macia). UL12-containing fractions were pooled and con-
centrated. Scheme 2: Pooled fractions from the Sepha-
rose column were loaded onto a 2-ml CHT-2 hydroxyap-
atite column (Bio-Rad, Hercules, CA) that had been
equilibrated in Buffer A1, washed with 15 ml Buffer A1,
and eluted with a 15-ml gradient from Buffer A1 to 0.5 M
potassium phosphate. Fractions from approximately 50
to 200 mM salt were collected, spin concentrated, diluted
into Buffer A1, then loaded again onto the same column
under the same conditions. The flowthrough from the
second run was pooled and concentrated. Typical yields
from approximately 5 g of cells were approximately 4 mg
of protein from Scheme 1 and approximately 1 mg of
protein from Scheme 2.
Nuclease assays
3H-labeled E. coli DNA was used as a substrate for
exonuclease activity and was prepared as follows. E. coli
strain AB2497 [thy2; see E. coli Genetic Stock Center
(CGSC) for details] was grown in M9 medium supple-
mented with 0.2% glucose, 1% casamino acids, 0.001%
thiamine, and 0.5 mg/ml thymidine. Two hundred micro-
liters of cells was added to 20 ml of the same media but
with 0.3 mg/ml thymidine, grown for 2 h, supplemented
with 100 mCi [3H] thymidine (371 mCi/mg, 92 Ci/mmol)
(Amersham International plc, Buckinghamshire, En-
gland), and grown overnight at 37°C. The cells were
centrifuged, resuspended in 1 ml 50 mM Tris–HCl, pH 8,
10 mM EDTA, 10 mg/ml RNase A, 0.5% SDS, 0.1 mg/ml
proteinase K, and incubated at 37°C overnight. The ly-
sate was extracted with phenol/chloroform/isoamyl alco-
hol, then with chloroform/isoamyl alcohol, then precipi-
tated with 0.3 M NaAc, pH 5.2, 70% ethanol. The precip-
itate was resuspended in 100 ml TE (10 mM Tris, pH 8, 1
mM EDTA). The final DNA concentration was 4 mg/ml,
with a specific activity of 2.7 3 104 CPM/mg. This DNA
was made single-stranded by boiling for 10 min and
quick-freezing.
Exonuclease activity was measured by the release
of acid-soluble radioactivity from 3H-labeled E. coli
DNA. Enzyme (10 ng) was incubated with 4 mg 3H-
DNA, 7.8 mg single-stranded salmon sperm DNA, 50
mM Tris–HCl, pH 9, 10 mM MgCl2, 5 mM b-mercapto-
ethanol, and 100 mg/ml BSA in a reaction volume of
200 ml. After 20 min at 37°C, the reaction was placed
on ice, added to 1 ml [5% TCA (trichloroacetic acid)
plus 0.25 mg/ml BSA], incubated on ice for 5 min, and
centrifuged for 5 min, and the soluble fraction was
added to scintillation fluid and counted in a Beckman
LS2800 scintillation counter. Less than 15% of total
radioactivity was released. Time course experiments
showed that the reaction was linear up to at least
40 min.
For endonuclease activity, 150 ng of enzyme was
added to 62 ng of plasmid pUC18, in a 20-ml reaction
volume with 50 mM Tris, pH 9, 5 mM MgCl2, 100 mg/ml
BSA, 5 mM b-mercaptoethanol. The reaction was incu-
bated for 2 h, and the products subjected to electro-
phoresis on a 0.8% agarose gel.
Transient complementation assay
Transient complementation was performed as de-
scribed previously (Martinez et al., 1992). Briefly, 1 3 106
freshly trypsinized exponentially growing Vero cells were
transfected with 8 mg of either pF19-CMV, pF19-AK, pF19-
AK(G336A/S338A), or pF19-AK(D340E). Twenty-four hours
posttransfection, the cells were superinfected with virus
AN-1 at an MOI of 1 PFU per cell. Twenty-four hours
postinfection, 5 ml of progeny viruses was harvested and
titered on complementing 6-5 cells for total yield. To
examine multiple rounds of viral infection, 0.5 ml of these
progeny was used to infect fresh 60-mm plates of 1 3 106
Vero cells. Four or 8 days postinfection, progeny were
harvested and titered on complementing 6-5 cells.
Defective viral stocks
Complementing 6-5 cells were transfected with
plasmids pF19-CMV, pF19-AK, pF19-AK(G336A/S338A),
and pF19-AK(D340E) as described above. Twenty-four
hours posttransfection, transfected cells were super-
infected with UL12 null mutant AN-1. Forty-eight hours
postinfection, virus progeny (p0) were harvested and
used to superinfect 150-mm flasks of 6-5 cells. Three
days postinfection, the progeny from this passage (p1)
were harvested.
Western blot
To analyze infected cell lysates, 1 3 106 cells in a
60-mm-diameter tissue culture dish were infected with
virus stocks at an MOI of 1 PFU per cell at 37°C. Cells
were collected at 12 h postinfection by centrifugation at
2000 rpm for 10 min in a Beckman TJ-6 centrifuge. Cell
pellets were rinsed with 13 PBS and resuspended in 100
ml 13 SDS–PAGE loading buffer (50 mM Tris–HCl, pH
6.8, 100 mM DTT, 2% SDS, 0.1% bromphenol blue, 10%
glycerol). Cell lysates in SDS–PAGE loading buffer were
boiled for 5 min, and 25-ml aliquots were subjected to
electrophoresis on an SDS–8% polyacrylamide gel. Pro-
tein was blotted onto Hybond ECL nitrocellulose mem-
brane (Amersham, Buckinghamshire, England). ECL (en-
hanced chemiluminescence) Western blotting analysis
was performed according to the manufacturer’s instruc-
tions (Amersham). To detect UL12 gene products, the
antibody BWp12 (Martinez et al., 1996b) (generously pro-
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vided by Peter Weber) was used as the primary antibody
at a dilution of 1:10,000 (in PBS containing 0.2% Tween
20) at room temperature for 1 h.
Indirect immunofluorescence
To perform immunofluorescence (IF) on transfected
cells, 1 3 106 Vero cells were transfected as described
above, plated onto 60-mm tissue culture plates with
glass coverslips, and processed 24 h posttransfection.
To perform IF on infected cells, Vero cells were grown
on coverslips and infected for 5 h at 37°C. Coverslips
were washed twice with PBS and fixed in 37% formal-
dehyde (Sigma) for 30 min. Cells were washed again
with PBS, permeabilized in 1% Triton X-100 for 5 min,
washed again, and incubated with 3% normal goat
serum (NGS) in PBS for 30 min. UL12 was detected
with monoclonal antibody Q1 (Banks et al., 1983), gen-
erously provided by Ken Powell. Q1 was diluted 1:1000
in 3% NGS and incubated with cells for 30 min. Fol-
lowing four PBS washes, rhodamine-conjugated goat
anti-rabbit secondary antibody was diluted 1:200 in 3%
NGS and added to the coverslips. After 30 min, cells
were washed five times with PBS and mounted onto
glass slides in glycerol gelatin containing 2.5%
DABCO. Cells were imaged on a Zeiss Axiovert 135
laser-scanning microscope (confocal) equipped with a
Zeiss 63X Plan Neofluar objective, as described in
Lukonis and Weller (1997). Collected images were
arranged and labeled with Adobe Photoshop 3.0.
ACKNOWLEDGMENTS
We thank Fred Homa for his generous gift of the UL12-expressing
recombinant baculovirus. We thank Ann D. Kwong for her generous gift
of the amplicon plasmid pF19-CMV. We thank Peter Weber for the
BWp12 polyclonal antibody and Ken Powell for the Q1 monoclonal
antibody. We thank Rik Martinez and Amelia Hopkins for construction of
plasmid B1 and the mutant UL12 baculoviruses. Finally, many thanks to
members of our laboratory for helpful discussions of this work and the
manuscript. This investigation was supported by Public Health Service
Grants AI21747 and AI37549.
REFERENCES
Ahrens, C. H., Russell, R. L., Funk, C. J., Evans, J. T., Harwood, S. H., and
Rohrmann, G. F. (1997). The sequence of the Orgyia pseudotsugata
multinucleocapsid nuclear polyhedrosis virus genome. Virology
229(2), 381–399.
Albrecht, J. C., Nicholas, J., Biller, D., Cameron, K. R., Biesinger, B.,
Newman, C., Wittmann, S., Craxton, M. A., Coleman, H., Fleckenstein,
B., and Honess, R. W. (1992). Primary structure of the herpesvirus
saimiri genome. J. Virol. 66(8), 5047–5058.
Ausubel, F. M., Brent, R., Kingston, R. E., Moore, D. D., Seidman, J. G.,
Smith, J. A., and Struhl, K., Eds. (1997). ‘‘Current Protocols in Molec-
ular Biology’’ (V. B. Chanda, Ed.), Vol. 1. Wiley, New York.
Ayres, M. D., Howard, S. C., Kuzio, J., Lopez-Ferber, M., and Possee,
R. D. (1994). The complete DNA sequence of Autographa californica
nuclear polyhedrosis virus. Virology 202, 586–605.
Baer, R. J., Bankier, A. T., Biggin, M. D., Deininger, P. L., Farrell, P. J.,
Gibson, T. J., Hatfull, G. F., Hudson, G. S., Satchwell, S. C., Seguin, C.,
Tuffnell, P. S., and Barrell, B. G. (1984). DNA sequence and expres-
sion of the B95-8 Epstein–Barr virus genome. Nature 310(5974),
207–211.
Bankier, A. T., Beck, S., Bohni, R., Brown, C. M., Cerny, R., Chee, M. S.,
Hutchinson, C. A., III, Kouzarides, T., Martignetti, J. A., Preddie, E.,
Satchwell, S. C., Tomlinson, P., Weston, K. M., and Barrell, B. G. (1991).
The DNA sequence of the human cytomegalovirus genome. DNA
Seq. 2(1), 1–12.
Banks, L., Purifoy, D. J. M., Hurst, P.-F., Killington, R. A., and Powell, K. L.
(1983). Herpes simplex virus non-structural proteins. IV. Purification
of the virus-induced deoxyribonuclease and characterization of the
enzyme using monoclonal antibodies. J. Gen. Virol. 64, 2249–2260.
Banks, L. M., Halliburton, I. W., Purifoy, D. J. M., Killington, R. A., and
Powell, K. L. (1985). Studies on the herpes simplex virus alkaline
nuclease: Detection of type-common and type-specific epitopes on
the enzyme. J. Gen. Virol. 66, 1–14.
Bataille, D., and Epstein, A. (1994). Herpes simplex virus replicative
concatemers contain L components in inverted orientation. Virology
203(2), 384–388.
Baylis, S. A., Purifoy, D. J. M., and Littler, E. (1989). The characterization
of the EBV alkaline deoxyribonuclease cloned and expressed in
E.coli. Nucleic Acids Res. 17(19), 7609–7621.
Baylis, S. A., Purifoy, D. J. M., and Littler, E. (1991). High-level expression
of the Epstein–Barr virus alkaline deoxyribonuclease using a recom-
binant baculovirus: Application to the diagnosis of nasopharyngeal
carcinoma. Virology 181, 390–394.
Berthomme, H., Fournel, S., and Epstein, A. L. (1996). Increased
transcomplementation properties of plasmids carrying HSV-1 origin
of replication and packaging signals. Virology 216, 437–443.
Bronstein, J. C., and Weber, P. C. (1996). Purification and characteriza-
tion of herpes simplex virus type 1 alkaline exonuclease expressed
in Escherichia coli. J. Virol. 70(3), 2008–2013.
Bronstein, J. C., Weller, S. K., and Weber, P. C. (1997). The product of the
UL12.5 gene of herpes simplex virus type 1 is a capsid-associated
nuclease. J. Virol. 71(4), 3039–3047.
Carmichael, E. P., Kosovsky, M. J., and Weller, S. K. (1988). Isolation and
characterization of herpes simplex virus type 1 host range mutants
defective in viral DNA synthesis. J. Virol. 62(1), 91–99.
Chung, Y., and Hsu, W. (1997). Purification of the infectious bovine
rhinotracheitis virus alkaline deoxyribonuclease expressed in Esch-
erichia coli. J. Vet. Med. Sci. 59(1), 35–38.
Costa, R. H., Draper, K. G., Banks, L., Powell, K. L., Cohen, G., Eisenberg,
R., and Wagner, E. K. (1983). High-resolution characterization of
herpes simplex virus type 1 transcripts encoding alkaline exonucle-
ase and a 50,000-dalton protein tentatively identified as a capsid
protein. J. Virol. 48(3), 591–603.
Davison, A. J., and Scott, J. E. (1986). The complete DNA sequence of
varicella-zoster virus. J. Gen. Virol. 67(9), 1759–1816.
de Bruyn-Kops, A., and Knipe, D. M. (1988). Formation of DNA replica-
tion structures in herpes virus-infected cells requires a viral DNA
binding protein. Cell 55, 857–868.
Deshmane, S. L., Raengsakulrach, B., Berson, J. F., and Fraser, N. W.
(1995). The replicating intermediates of herpes simplex virus type 1
DNA are relatively short. J. Neurovirol. 1, 165–176.
deWind, N., Peeters, B. P. H., Zijderveld, A., Gielkens, A. L. J., Berns,
A. J. M., and Kimman, T. G. (1994). Mutagenesis and characterization
of a 41-kilobase-pair region of the pseudorabies virus genome:
Transcription map, search for virulence genes, and comparison with
homologs of herpes simplex virus type 1. Virology 200, 784–790.
Dijkstra, J. M., Visser, N., Mettenleiter, T. C., and Klupp, B. G. (1996).
Identification and characterization of pseudorabies virus glycopro-
tein gM as a nonessential virion component. J. Virol. 70(8), 5684–
5688.
Draper, K. G., Devi-Rao, G., Costa, R. H., Blair, E. D., Thompson, R. L.,
and Wagner, E. K. (1986). Characterization of the genes encoding
herpes simplex virus type 1 and type 2 alkaline exonucleases and
overlapping proteins. J. Virol. 57(3), 1023–1036.
455UL12 EXONUCLEASE MUTANTS
Ensser, A., Pflanz, R., and Fleckenstein, B. (1997). Primary structure of
the alcelaphine herpesvirus 1 genome. J. Virol. 71(9), 6517–6525.
Francke, B., and Garrett, B. (1982). The effect of a temperature-sensitive
lesion in the alkaline DNase of herpes simplex virus type 2 on the
synthesis of viral DNA. Virology 116, 116–127.
Fraser, M. J. (1994). Endo-exonucleases: Enzymes involved in DNA
repair and cell death? BioEssays 16(10), 761–766.
Frenkel, N., Singer, O., and Kwong, A. D. (1994). Minireview: The herpes
simplex virus amplicon—A versatile defective virus vector. Gene
Ther. 1(Suppl. 1), S40–S46.
Gompels, U. A., Nicholas, J., Lawrence, G., Jones, M., Thomson, B. J.,
Martin, M. E., Efstathiou, S., Craxton, M., and Macaulay, H. A. (1995).
The DNA sequence of Human Herpesvirus-6: Structure, coding con-
tent, and genome evolution. Virology 209, 29–51.
Graves-Woodward, K. L., Gottlieb, J., Challberg, M. D., and Weller, S. K.
(1997). Biochemical analyses of mutations in the HSV-1 helicase-
primase that alter ATP hydrolysis, DNA unwinding, and coupling
between hydrolysis and unwinding. J. Biol. Chem. 272(7), 4623–4630.
Hoffmann, P. J., and Cheng, Y.-C. (1978). The deoxyribonuclease in-
duced after infection of KB cells by herpes simplex virus type 1 or
type 2. J. Biol. Chem. 253(10), 3557–3562.
Hoffmann, P. J., and Cheng, Y.-C. (1979). DNase induced after infection
of KB cells by herpes simplex virus type 1 or type 2. J. Virol. 32(2),
449–457.
Hong, Z., Ferrari, E., Wright-Minogue, J., Chase, R., Risano, C., Seelig,
G., Lee, C.-G., and Kwong, A. D. (1996). Enzymatic characterization of
hepatitis C virus NS3/4A complexes expressed in mammalian cells
by using the herpes simplex virus amplicon system. J. Virol. 70(7),
4261–4268.
Hsiang, C.-Y., Ho, T.-Y., and Chang, T.-J. (1996). Identification of a pseu-
dorabies virus UL12 (deoxyribonuclease) gene. Gene 177, 109–113.
Keir, H. M., and Gold, E. (1963). Deoxyribonucleic acid nucleotidyltrans-
ferase and deoxyribonuclease from cultured cells infected with her-
pes simplex virus. Biochim. Biophys. Acta 72, 263–276.
Knopf, C. W., and Weisshart, K. (1990). Comparison of exonucleolytic
activities of herpes simplex virus type-1 DNA polymerase and
DNase. Eur. J. Biochem. 191, 263–273.
Kovall, R., and Matthews, B. W. (1997). Toroidal structure of lambda-
exonuclease. Science 277, 1824–1827.
Kozak, M. (1986). Point mutations define a sequence flanking the AUG
initiator codon that modulates translation by eukaryotic ribosomes.
Cell 44, 283–292.
Lieber, M. R. (1997). The FEN-1 family of structure-specific nucleases in
eukaryotic DNA replication, recombination, and repair. BioEssays
19(3), 233–240.
Lin, S.-F., Hsu, T.-Y., Liu, M.-Y., Lin, L.-S., Yang, H.-L., Chen, J.-Y., and Yang,
C.-S. (1995). Characterization of Epstein–Barr virus DNase and its
interaction with the major DNA binding protein. Virology 208, 712–
722.
Lin, S.-F., Lin, S.-W., Hsu, T.-Y., Liu, M.-Y., Chen, J.-Y., and Yang, C.-S.
(1994). Functional analysis of the amino terminus of Epstein–Barr
virus deoxyribonuclease. Virology 199, 223–227.
Lukonis, C. J., and Weller, S. K. (1997). Formation of herpes simplex virus
type 1 replication compartments by transfection: Requirements and
localization to nuclear domain 10. J. Virol. 71(3), 2390–2399.
Malik, A. K., and Weller, S. K. (1996). Use of transdominant mutants of
the origin-binding protein (UL9) of herpes simplex virus type 1 to
define functional domains. J. Virol. 70(11), 7859–7866.
Martinez, R., Sarisky, R. T., Weber, P. C., and Weller, S. K. (1996a). Herpes
simplex virus type 1 alkaline nuclease is required for efficient pro-
cessing of viral DNA replication intermediates. J. Virol. 70(4), 2075–
2085.
Martinez, R., Shao, L., Bronstein, J. C., Weber, P. C., and Weller, S. K.
(1996b). The product of a 1.9-kb mRNA which overlaps the HSV-1
alkaline nuclease gene (UL12) cannot relieve the growth defects of a
null mutant. Virology 215, 152–164.
Martinez, R., Shao, L., and Weller, S. K. (1992). The conserved helicase
motifs of the herpes simplex virus type 1 origin-binding protein UL9
are important for function. J. Virol. 66, 6735–6746.
McGeoch, D. J., Dalrymple, M. A., Davison, A. J., Dolan, A., Frame, M. C.,
McNab, D., Perry, L. J., Scott, J. E., and Taylor, P. (1988). The complete
DNA sequence of the long unique region in the genome of herpes
simplex virus type 1. J. Gen. Virol. 69, 1531–1574.
Morrison, J. M., and Keir, H. M. (1968). A new DNA-exonuclease in cells
infected with herpes virus: Partial purification and properties of the
enzyme. J. Gen. Virol. 3, 337–347.
Nicholas, J. (1996). Determination and analysis of the complete nucle-
otide sequence of human herpesvirus 7. J. Virol. 70(9), 5975–5989.
Patel, A. H., Subak-Sharpe, J. H., Stowe, N. D., Marsden, H. S., Maclean,
J. B., and Dargan, D. J. (1996). Suppression of amber nonsense
mutations of herpes simplex virus type 1 in a tissue culture system.
J. Gen. Virol. 77, 199–209.
Poloumienko, A., and Krell, P. (1996). Identification of the putative p22,
gp16, calyx protein, p25, exonuclease and p26 genes of a baculovi-
rus pathogenic to the spruce budworm, Cf NPV. [Unpublished Gen-
Bank submission]
Puvion-Dutilleul, F., Laithier, M., and Sheldrick, P. (1985). Ultrastructural
localization of the herpes simplex virus major DNA-binding protein in
the nucleus of infected cells. J. Gen. Virol. 66, 15–30.
Puvion-Dutilleul, F., and Pichard, E. (1986). Viral alkaline nuclease in
intranuclear dense bodies induced by herpes simplex infection. Biol.
Cell 58(1), 15–22.
Quinlan, M. P., Chen, L. B., and Knipe, D. M. (1984). The intranuclear
location of a herpes simplex virus DNA-binding protein is determined
by the status of viral DNA replication. Cell 36, 857–868.
Randall, R. E., and Dinwoodie, N. (1986). Intranuclear localization of
herpes simplex virus immediate-early and delayed-early proteins:
Evidence that ICP4 is associated with progeny virus DNA. J. Gen.
Virol. 67, 2163–2177.
Rawlinson, W. D., Farrell, H. E., and Barrell, B. G. (1996). Analysis of the
complete DNA sequence of murine cytomegalovirus. J. Virol. 70(12),
8833–8849.
Roizman, B., and Sears, A. E. (1996). Herpes simplex viruses and their
replication. In ‘‘Fundamental Virology’’ (B. N. Fields, D. M. Knipe, and
P. M. Howley, Eds.), Third ed., pp. 1043–1107. Lippincott - Raven,
Philadelphia.
Russo, J. J., Bohenzky, R. A., Chien, M. C., Chen, J., Yan, M., Maddalena,
D., Parry, J. P., Peruzzi, D., Edelman, I. S., Chang, Y., and Moore, P. S.
(1996). Nucleotide sequence of the Kaposi sarcoma-associated her-
pesvirus (HHV8). Proc. Natl. Acad. Sci. USA 93(25), 14862–14867.
Severini, A., Morgan, A. R., Tovell, D. R., and Tyrrell, D. L. (1994). Study
of the structure of replicative intermediates of HSV-1 DNA by pulsed-
field gel electrophoresis. Virology 200(2), 428–435.
Shao, L., Rapp, L. M., and Weller, S. K. (1993). Herpes simplex virus 1
alkaline nuclease is required for efficient egress of capsids from the
nucleus. Virology 196(1), 146–162.
Sheaffer, A. K., Weinheimer, S. P., and Tenney, D. J. (1997). The human
cytomegalovirus UL98 gene encodes the conserved herpesvirus
alkaline nuclease. J. Gen. Virol. 78, 2953–2961.
Steven, A. C., and Spear, P. G. (1997). Herpesvirus capsid assembly and
envelopment. In ‘‘Structural Biology of Viruses’’ (W. Chiu, R. M. Bur-
nett, and R. Garcea, Eds.), pp. 312–351. Oxford Univ. Press, New York.
Stolzenberg, M.-C., and Ooka, T. (1990). Purification and properties of
Epstein–Barr virus DNase expressed in Escherichia coli. J. Virol.
64(1), 96–104.
Strobel-Fidler, M., and Francke, B. (1980). Alkaline deoxyribonuclease
induced by herpes simplex virus type 1: Composition and properties
of the purified enzyme. Virology 103, 493–501.
Telford, E. A., Watson, M. S., McBride, K., and Davison, A. J. (1992). The
DNA sequence of equine herpesvirus-1. Virology 189(1), 304–316.
Thomas, M. S., Banks, L. M., Purifoy, D. J. M., and Powell, K. L. (1988).
Production of antibodies of predetermined specificity against herpes
simplex virus DNA polymerase and their use in characterization of
the enzyme. J. Virol. 62(5), 1550–1557.
456 GOLDSTEIN AND WELLER
Thomas, M. S., Gao, M., Knipe, D. M., and Powell, K. L. (1992). Associ-
ation between the herpes simplex virus major DNA-binding protein
and alkaline nuclease. J. Virol. 66(2), 1152–1161.
Turco, A., and Pignatti, P. F. (1988). Viral and cellular deoxyribonucle-
ases are associated with herpes simplex virus replicative interme-
diates. Microbiologica 11, 321–328.
Virgin, H. W. I., Latreille, P., Wamsley, P., Hallsworth, K., Weck, K. E., Dal
Canto, A. J., and Speck, S. H. (1997). Complete sequence and
genomic analysis of murine gammaherpesvirus 68. J. Virol. 71(8),
5894–5904.
Vlcek, C., Benes, V., Lu, Z., Kutish, G. F., Paces, V., Rock, D., Letchworth,
G. J., and Schwyzer, M. (1995). Nucleotide sequence analysis of a
30-kb region of the bovine herpesvirus 1 genome which exhibits a
colinear gene arrangement with the UL21 to UL4 genes of herpes
simplex virus. Virology 210(1), 100–108.
Weller, S. K. (1995). Herpes simplex virus DNA replication and genome
maturation. In ‘‘The DNA Provirus: Howard Temin’s Scientific Legacy’’
(G. M. Cooper, R. G. Temin, and B. Sugden, Eds.), pp. 189–213. ASM
Press, Washington, DC.
Weller, S. K., Lee, K. J., Sabourin, D. J., and Schaffer, P. A. (1983). Genetic
analysis of temperature-sensitive mutants which define the gene for
the major herpes simplex virus type 1 DNA-binding protein. J. Virol.
45, 354–366.
Weller, S. K., Seghatoleslami, R. M., Shao, L., Rowse, D., and Car-
michael, E. P. (1990). The herpes simplex virus type 1 alkaline
nuclease is not essential for viral DNA synthesis: Isolation and
characterization of a lacZ insertion mutant. J. Gen. Virol. 71, 2941–
2952.
Zhang, X., Efstathiou, S., and Simmons, A. (1994). Identification of novel
herpes simplex virus replicative intermediates by field inversion gel
electrophoresis: Implications for viral DNA amplification strategies.
Virology 202, 530–539.
457UL12 EXONUCLEASE MUTANTS
